Vivek Pradhan Selected Research

ropsacitinib

1/2022

Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Vivek Pradhan Research Topics

Disease

2	Ulcerative Colitis 05/2019 - 01/2017
2	Crohn Disease (Crohn's Disease) 01/2018 - 01/2017
1	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2022
1	Infections 01/2018
1	Progressive Multifocal Leukoencephalopathy 01/2018
1	Leukopenia 01/2018
1	Multiple Sclerosis 01/2018
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2018
1	Headache (Headaches) 06/2016

Drug/Important Bio-Agent (IBA)

4	ontamalimabIBA 05/2019 - 01/2017
2	Cell Adhesion Molecule-1IBA 05/2019 - 01/2018
2	Monoclonal AntibodiesIBA 05/2019 - 01/2018
1	TYK2 Kinase (Tyrosine Kinase 2)IBA 01/2022
1	ropsacitinibIBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 05/2019
1	LigandsIBA 01/2018
1	Natalizumab (Tysabri)FDA Link 01/2018
1	Immunosuppressive Agents (Immunosuppressants)IBA 01/2018
1	IntegrinsIBA 01/2018
1	Alanine Transaminase (SGPT)IBA 06/2016

Therapy/Procedure

4	Therapeutics 01/2022 - 01/2017
1	Remission Induction 01/2017